Admiral pubs boss: business rates will ‘kill off the high street’ February 23, 2026 The boss of a northern-based pubs company has claimed business rates will “kill off” the high street as well as pubs unless the levy is fundamentally reformed. Chris Jowsey, chief executive of Admiral Taverns, told City AM the government must deliver on its pledge to overhaul the business rates system, which he said “penalises bricks [...]
Three more interest rate cuts could come, Bank of England official says February 23, 2026 The Bank of England could make three more interest rate cuts in order to reach its neutral level as inflation drops back to two per cent over the coming year, a Monetary Policy Committee member has suggested. Alan Taylor, an external member who has consistently voted for larger interest rate cuts over the past year [...]
WFH requests could go to tribunal under Labour’s employment reforms February 23, 2026 Lawyers are warning that Labour’s plans to make flexible working the default could place additional legal and administrative burdens on British businesses. Under the proposed changes employees would be able to appeal an employer’s decision to refuse a flexible working request more easily through the Employment Tribunal. Lawyers at TWM Solicitors explained that the employer’s [...]
Inside Sarah Ferguson’s £100k-a-week rehab with lakeside apartment and round-the-clock therapy February 23, 2026 As Sarah Ferguson checks out of the world's most expensive rehab, we revisit what makes Paracelsus a perfect retreat for the disgraced.
KBRA Assigns Preliminary Ratings to Ares European Direct Lending CLO 2 Sarl February 23, 2026 KBRA UK (KBRA) assigns preliminary ratings to six classes of Notes issued by Ares European Direct Lending CLO 2 Sarl, a cash flow collateralized loan obligation (CLO) backed by a diversified portfolio of middle market corporate loans. This transaction is a multicurrency European middle market CLO. Ares European Direct Lending CLO 2 Sarl is managed [...]
Orbia Honored as a Top Company in its Industry in the S&P Global Sustainability Yearbook for Fifth Consecutive Year February 23, 2026 Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*), has been named a member of the S&P Global Sustainability Yearbook for the fifth consecutive year, which honors best-in-class global sustainability companies evaluated through the S&P Global Corporate Sustainability Assessment (CSA). “Orbia’s continued inclusion in this leading sustainability ranking underscores our conviction that sustainability is a driver [...]
BSE (formerly Bombay Stock Exchange) Selects ITRS to Strengthen Real-Time Monitoring and Operational Resilience February 23, 2026 Asia’s Oldest Stock Exchange Partners with ITRS to Strengthen Monitoring and Compliance
Ares Management Prices European Direct Lending CLO II at Over €300 Million February 23, 2026 Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the pricing of its second European Direct Lending Collateralized Loan Obligation, Ares European Direct Lending CLO II (“EDL CLO II”), at over €300 million. Consistent with the underlying composition of its predecessor, EDL CLO II is a diversified CLO comprised entirely [...]
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights February 23, 2026 Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4 million Prothena expects the full year 2026 net cash used in operating and investing activities to be $50 to $55 million and expects to end the year with approximately $255 million in cash (midpoint). Financial guidance does not include the potential to earn up to $105 million in aggregate clinical milestone payments from strategic partners in 2026 Roche initiated the Phase 3 PARAISO trial evaluating prasinezumab in early-stage Parkinson’s disease in 4Q 2025; primary completion expected in 2029 Novo Nordisk initiated the Phase 3 CLEOPATTRA trial evaluating coramitug in ATTR amyloidosis with cardiomyopathy in 4Q 2025; primary completion expected in 2029 Bristol Myers Squibb fully enrolled the Phase 2 TargetTau-1 trial evaluating BMS-986446 in early Alzheimer’s disease with primary completion expected in 1H 2027, completed a Phase 1 trial evaluating a subcutaneous formulation of BMS-986446 and obtained Fast Track designation from the U.S. FDA for BMS-986446 for the treatment of Alzheimer’s disease Prothena presented preclinical data on its TDP-43 CYTOPE® program at Neuroscience 2025 (SfN) and at the International Symposium on ALS/MND demonstrating the potential of Prothena’s CYTOPE® technology to target intracellular disease pathways At the Extraordinary General Meeting on November 19, 2025 Prothena obtained shareholder approval to reduce share capital to create distributable reserves to support a share redemption program to be conducted in 2026 if deemed appropriate Potential to earn up to $105 million in aggregate clinical milestone payments by end of 2026 related to the advancement of both coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb
ActiveCampaign Backs Autonomous Marketing with Results Guarantee February 23, 2026 The company becomes first in category to guarantee marketing outcomes, signaling strong platform performance & commitment to customer success